Figure 6.

Control results for the in vivo use of conditionally replicative adenovirus (CRAd) Ad5/3‐Cox2CRAd‐ΔE3‐ADP‐Luc to monitor the pancreatic cancer cell response to gemcitabine. Established MiaPaCa‐2 xenografts in BALB/c nu/nu mice were injected i.p. with PBS weekly, then on days 33 (a) and 40 (b), 1.0 × 10¹⁰ viral particles CRAd(Ad5/3‐Cox2CRAd‐ΔE3‐ADP‐Luc) in 50 μL PBS were injected intratumorally. On day 36 (a) and day 42 (b), tumors (upper left panel) and bioluminescence were measured (lower left panel), and tumors were removed and stained with H&E (upper right panel) and Ki‐67 (lower right panel). (c) Gross tumor volume and CRAd bioluminescence were closely correlated (R = 0.94).